UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PAR PHARMACEUTICAL, INC.,

Petitioner,

V.

NOVARTIS AG,

Patent Owner.

Case IPR2016-01479 Patent No. 9,006,224

DECLARATION IN SUPPORT OF PATENT OWNER NOVARTIS'S MOTION FOR *PRO HAC VICE* ADMISSION OF CHARLOTTE JACOBSEN UNDER 37 C.F.R. § 42.10

NOVARTIS EXHIBIT 2037 Par v Novartis, IPR 2016-01479 Page 1 of 5




- 1. I, Charlotte Jacobsen, am more than twenty-one years of age, am competent to present this declaration, and have personal knowledge of the facts set forth herein.
- 2. This declaration is given in support of Patent Owner Novartis's Motion for *Pro Hac Vice* Admission.
- 3. I am a partner at the law firm of Fitzpatrick, Cella, Harper & Scinto, in the firm's New York office.
- 4. I have been a patent litigation attorney for more than thirteen years. I have been litigating patent cases for this entire time period and have been involved in numerous cases involving patent validity and infringement, at both the District Court and the Federal Circuit. I have extensive experience in bench trials. I have also been involved in *inter partes* review proceedings before the Board. A significant portion of my work has involved biological and chemical arts, with particular emphasis on pharmaceuticals. I am, therefore, an experienced litigating attorney.
- 5. I am a member in good standing of the State Bar of New York and the Bar of England and Wales. I have never been suspended or disbarred from practice before any court or administrative body.

Find authenticated court documents without watermarks at docketalarm.com.



NOVARTIS EXHIBIT 2037

- 6. No court or administrative body has ever denied my application for admission to practice before it.
- 7. No court or administrative body has ever imposed sanctions or contempt citations on me.
- 8. I have read and will comply with the Office Patent Trial Practice Guide and the Board's Rules of Practice for Trials set forth in part 42 of 37 C.F.R.
- 9. I understand that I will be subject to the Office's Rules of Professional Conduct set forth in 37 C.F.R. §§ 11.101 *et seq.* and disciplinary jurisdiction under 37 C.F.R. § 11.19(a).
- 10. I have applied to appear *pro hac vice* in three (3) other proceedings before the Office in the last three (3) years. In Noven Pharm., Inc. v. Novartis AG *et al.*, *Inter Partes* Reviews 2014-00549 and 2014-00550, and Par Pharmaceuticals, Inc. v. Novartis AG, *Inter Partes* Review 2016-00084, I sought and was granted permission to appear *pro hac* vice.
- 11. I have an established familiarity with the subject matter at issue in this proceeding. I have been involved substantively in the instant matter and in District Court litigation involving the same patent. I have read in detail and





understand the Petition filed by Petitioner and the challenged patent, U.S. Patent 9,006,224 ("the '224 patent"). I have also reviewed all the exhibits relied upon by Petitioner and Patent Owner in this proceeding, including each of the references cited in instituted Grounds 1-4.

- 12. I have engaged in extensive strategic and substantive discussions regarding this proceeding with Nicholas N. Kallas, who is the lead counsel for Patent Owner in this proceeding and a registered practitioner (Reg. No. 31,530). I have also engaged in extensive substantive discussions with experts concerning issues relevant to this proceeding.
- 13. Therefore, I have an established familiarity with the subject matter at issue in this proceeding.
- 14. I declare further that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the '224 patent.

NOVARTIS EXHIBIT 2037 Par v Novartis, IPR 2016-01479 Page 4 of 5



Dated: March 21, 2017

Charlotte Jacobsen

NOVARTIS EXHIBIT 2037 Par v Novartis, IPR 2016-01479 Page 5 of 5

